MediWound Ltd.

NASDAQ:MDWD

Biotechnology

Healthcare
$13.68 -0.60%

-$0.09 today

Market cap
$176.61M
Beta
0.15
P/E (TTM)
-7.0
EPS (TTM)
-$2.03
52W Low $13.54High $21.26

Volume 0.16M

Average 0.09M

MDWD EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

MediWound Ltd.NASDAQ: MDWD

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$2.59M, compared with -$363K a year earlier. Trailing-twelve-month EBITDA was -$14.84M.

Context

  • EBITDA amounted to 126.6% of revenue in FY2025, down 11.5 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 5 analysts of -$19.87M (+7.5%) for the fiscal year ending Dec 2026, a slowdown from the +23.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.59M+49.9% QoQ
Last fiscal yearDec 2025
-$21.47M+23.1% YoY
LTMMar 2026
-$14.84M+39.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-613.8%-71.6%+542.2 pp
1 year+23.1%+7.5%-15.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(21.47M) USD
Year-over-year change
+23.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How MDWD compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.0% is the 2nd highest of 9, against a peer median of -57.7%.
  • EBITDA amounts to 102.5% of revenue for MDWD, versus a peer median of 1509.8%.
MDWD Competitors
EBITDA for MDWD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDWDMediWound Ltd.LTM Mar 2026-$14.84M USD+39.0%—102.5%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$35.22M USD———
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026-$35.76M USD-89.6%——
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$45.49M USD-75.7%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M USD+20.1%—161.1%
TARAProtara Therapeutics, Inc.LTM Mar 2026-$62.94M USD-39.6%——
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026-$69.83M USD-147.0%——
IVVDInvivyd, Inc.LTM Mar 2026-$75.72M USD+45.7%—135.5%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$158.55M USD-341.7%—8932.3%
Peer median (excluding MDWD) —-57.7%—1509.8%

Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue23.76M26.5M18.69M20.22M16.96M
Cost of Revenue14.99M13.33M15.11M17.59M13.71M
Gross Profit8.77M13.17M3.58M2.63M3.25M
Gross Margin36.9%49.7%19.1%13.0%19.2%
Research & Development10.26M10.18M7.47M8.88M14.32M
Selling, General & Admin9.45M10.37M11.38M12.91M13.93M
Operating Expenses19.99M20.83M19.08M22.02M28.53M
Depreciation & Amortization1.24M1.27M1.3M1.48M1.86M
EBITDA(11.38M)(18.25M)(4.8M)(27.93M)(21.47M)
EBITDA Margin-47.9%-68.9%-25.7%-138.1%-126.6%
Operating Income(11.22M)(7.66M)(15.5M)(19.38M)(25.28M)
Operating Margin-47.2%-28.9%-83.0%-95.8%-149.1%
Interest Income11K270K2.34M2.05M1.86M
Interest Expense167K162K335K561K663K
Other Income / Expenses(2.3M)(11.86M)8.97M(10.78M)1.57M
Income Before Tax(13.52M)(19.52M)(6.53M)(30.16M)(23.71M)
Pre-Tax Margin-56.9%-73.7%-35.0%-149.2%-139.8%
Income Tax Expense27K78K185K61K169K
Net Income(13.55M)(19.6M)(6.72M)(30.22M)(23.88M)
Net Margin-57.0%-74.0%-35.9%-149.5%-140.8%
EPS (Basic)(3.48)(3.93)(0.75)(3.03)(2.10)
EPS (Diluted)(3.48)(3.93)(0.75)(3.03)(2.10)
Weighted Avg Shares3.89M4.99M9.01M9.96M11.38M
Weighted Avg Shares (Diluted)3.89M4.99M9.01M9.96M11.38M

MediWound Ltd.

NASDAQ:MDWD

Intrinsic Alpha fair value

Locked

Current Price

$13.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.